Rheumatoid Arthritis Memory B Cells and Abatacept

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 2, 2019

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Abatacept

Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.

DRUG

DMARDs

Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dartmouth-Hitchcock Medical Center

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

NYU Langone Health

OTHER

NCT03652961 - Rheumatoid Arthritis Memory B Cells and Abatacept | Biotech Hunter | Biotech Hunter